Revisiting inconsistency in large pharmacogenomic studies
نویسندگان
چکیده
منابع مشابه
Revisiting inconsistency in large pharmacogenomic studies
In 2013, we published a comparative analysis of mutation and gene expression profiles and drug sensitivity measurements for 15 drugs characterized in the 471 cancer cell lines screened in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE). While we found good concordance in gene expression profiles, there was substantial inconsistency in the drug response...
متن کاملPharmacogenetic and Pharmacogenomic Studies
The topics discussed in this article are concerned with studying genomic polymorphism and identifying new therapeutic targets, the role of genetics in preclinical and clinical drug development, and cultural, regulatory and logistical aspects of the development of pharmacogenetics in France. The conclusions are that from a physiological, biochemical or genomic point of view, the study of human g...
متن کاملIntegrating epigenomics into pharmacogenomic studies
The goal of personalized medicine is to recommend drug treatment based on an individual's genetic makeup. Pharmacogenomic studies utilize two main approaches: candidate gene and whole-genome. Both approaches analyze genetic variants such as single nucleotide polymorphisms (SNPs) to identify associations with drug response. In addition to DNA sequence variations, non-genetic but heritable epigen...
متن کاملTowards Large-Scale Inconsistency Measurement
We investigate the problem of inconsistency measurement on large knowledge bases by considering stream-based inconsistency measurement, i. e., we investigate inconsistency measures that cannot consider a knowledge base as a whole but process it within a stream. For that, we present, first, a novel inconsistency measure that is apt to be applied to the streaming case and, second, stream-based ap...
متن کاملPharmacoGx: an R package for analysis of large pharmacogenomic datasets
UNLABELLED Pharmacogenomics holds great promise for the development of biomarkers of drug response and the design of new therapeutic options, which are key challenges in precision medicine. However, such data are scattered and lack standards for efficient access and analysis, consequently preventing the realization of the full potential of pharmacogenomics. To address these issues, we implement...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: F1000Research
سال: 2017
ISSN: 2046-1402
DOI: 10.12688/f1000research.9611.3